Welcome to the North Dakota Department of Health (NDDoH) Tuberculosis (TB) Program website. The TB program is divided into three sections: Active TB Surveillance, Latent TB Surveillance, and Class B Refugee monitoring.
The NDDoH TB Prevention and Control Program collaborates with clinicians and local public health units to ensure that persons with TB receive effective and timely treatment and that contact investigations are performed to minimize the spread of TB.
The NDDoH TB surveillance program receives funding from the U.S. Centers for Disease Control and Prevention (CDC) to collect information about TB infection and Latent TB infection diagnoses among North Dakota residents. TB data is used to characterize and predict the changing epidemic at the local, regional and national levels. North Dakota TB data is summarized to help the NDDoH to:
- Monitor the incidence and estimated prevalence of TB in the state.
- Utilize surveillance data to better characterize the risks and needs of people infected with TB in North Dakota.
- Assess the risks for TB infection and develop effective TB prevention programs
- Justify necessary federal and state funding to support continued TB prevention, services and surveillance activities.
The NDDoH Class B Refugee monitoring program serves to assure that additional medical follow-up for refugees who require further evaluation of possible TB infection is completed.
Nationwide Shortage of Tuberulin Skin Test Antigens
The Centers for Disease Control and Prevention (CDC) is expecting a 3 to 10 month nationwide shortage of APLISOL®, a product of Par Pharmaceuticals. APLISOL® is one of two purified-protein derivative (PPD) tuberculin antigens that are licensed by the United States Food and Drug Administration (FDA) for use in performing tuberculin skin tests.
Follow this link for recommendations on testing and screening for tuberculosis during this period of shortage. Nationwide
Shortage of Tuberculin Skin Test Antigens.